

## Glenmark Pharmaceuticals Ltd

[View the current Glenmark Pharmaceuticals Ltd Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/23569-Glenmark+Pharmaceuticals+Ltd.html)

(<http://www.bioportfolio.com/biocorporate/23569-Glenmark+Pharmaceuticals+Ltd.html>)

### Contact Details:

750 Corporate Drive

Mahwah

New Jersey

07430

United States of America

Tel: [1 201] 684 8000

Fax: [1 201] 831 0080

Email: [api\\_usa@glenmarkpharma.com](mailto:api_usa@glenmarkpharma.com)

Glenmark Pharmaceuticals Limited [Glenmark] is an India-based growing pharmaceutical company headquartered at Mumbai [formerly, Bombay]. Incorporated in 1977, the Company is focused on the manufacture and marketing of formulation products and active pharmaceutical ingredients [API] in India as well as globally and enjoys a diversified and growing presence in regulated and developing international markets. Over the past five years, the Company has also catalysed its growth through investment in dedicated research and development including cutting-edge New Chemical Entity [NCE] research.

### Recent Publications by Glenmark Pharmaceuticals Ltd:



- [Lornoxicam efficacy in acute pain \(LEAP\) trial.](#)  
*Parenteral non-steroidal anti-inflammatory drugs (NSAIDs) are useful...*8th May, 2009  
Glenmark Pharmaceuticals Ltd, Mumbai.- J Indian Med Assoc. 2008 Dec;106(12):811-3.
- [Evaluation of fixed dose combination \(FDC\) of telmisartan+ramipril usage in patients with micro-albuminuria and persistent hypertension: A TRIUMPH study.](#)  
*Micro-albuminuria is a marker for declining kidney function and predicts...*11th September, 2008  
Medical Services Department, Glenmark Pharmaceuticals Ltd, Mumbai.- J Indian Med Assoc. 2008 Mar;106(3):191-4, 196.
- [An open prospective study on postmarketing evaluation of the efficacy and tolerability of diacerein in osteo-arthritis of the knee \(DOK\).](#)  
*According to World Health Organisation osteo-arthritis is the second...*3rd September, 2008  
Glenmark Pharmaceuticals Limited, Mumbai.- J Indian Med Assoc. 2008 Jan;106(1):54-6, 58.
- [Comparative assessment of the bioavailability, efficacy and safety of a modified-release \(MR\) carbonyl iron tablet and oral conventional iron preparation in adult Indian patients with nutritional iron deficiency anaemia.](#)

*The objective of the study is to evaluate the bioavailability, efficacy...* 16th November, 2005  
 Glenmark Pharmaceuticals Ltd, Mumbai.- J Indian Med Assoc. 2005 Jun;103(6):338-42.

- [A pilot study for evaluation of the efficacy and safety of telmisartan in reducing microalbuminuria in hypertensive patients with type 2 diabetes mellitus.](#)

*To evaluate efficacy and tolerability of telmisartan, an angiotensim II...* 18th October, 2005  
 Glenmark Pharmaceuticals Ltd, Mumbai 400026.- J Indian Med Assoc. 2005 Mar;103(3):187-91.

- [Role of parecoxib in pre-emptive analgesia: comparison of the efficacy and safety of pre- and postoperative parecoxib in patients undergoing general surgery.](#)

*Management of acute postoperative pain remains sub-optimal despite the...* 9th March, 2005  
 Glenmark Pharmaceuticals Ltd, Mumbai 400026.- J Indian Med Assoc. 2004 May;102(5):272, 274, 276-8.

- [Comparative evaluation of the efficacy, safety, and tolerability of rosuvastatin 10 mg with atorvastatin 10 mg in adult patients with hypercholesterolaemia: the first Indian study.](#)

*To compare the efficacy, safety and tolerability of rosuvastatin 10mg with...* 9th July, 2004  
 Glenmark Pharmaceuticals Ltd, Mumbai 400026.- J Indian Med Assoc. 2004 Jan;102(1):48-50, 52.

- [Efficacy and safety of a combination of metformin and rosiglitazone in patients with type 2 diabetes mellitus--a postmarketing study.](#)

*The efficacy and safety of combined metformin and rosiglitazone therapy in...* 6th August, 2003  
 Medical Services, Glenmark Pharmaceuticals Limited, Mumbai 400026.- J Indian Med Assoc. 2003 Feb;101(2):113-4, 123.

**Press Releases on Glenmark Pharmaceuticals Ltd:**

<a href="#">Reportlinker Adds Imaging Agents - A Worldwide Market Review</a>	20th November, 2009	Reportlinker	<i>NEW YORK, Nov. 20 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Imaging Agents - A Worldwide Market Review http://www.reportlinker.com</i>
<a href="#">AstraZeneca and the Philadelphia Department of Public Health Provide Free Medicines to Pennsylvania's Uninsured</a>	20th November, 2009	AstraZeneca	<i>WILMINGTON, Del., Nov. 20 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) and the Philadelphia Department of Public Health announced today at a press conference at Philadelphia Health Care Center #6</i>
<a href="#">Impax Laboratories Drives Stronger Performance with IBM Business Analytics</a>	20th November, 2009	IBM	<i>-- C-level Executive Committee can now easily pull together a single view of net sales, profitability and competitive market share information, helping them to determine whether</i>

[Alexza Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference](#)

19th November, 2009 Alexza Pharmaceuticals, Inc.

MOUNTAIN VIEW, Calif., Nov. 19 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that its corporate presentation will be webcast live during the 21st Annual Piper

[AUDIO from Medialink and Ortho-McNeil-Janssen Pharmaceuticals Inc.: Getting Ready for Cold and Flu Season](#)

19th November, 2009 Medialink

NEW YORK, Nov. 19 /PRNewswire/ -- As the seasons change, another season of coughs and running noses is here. Here's more on preparing yourself. Listen to this report from Ortho-McNeil-Janssen

## BioNews Results for Glenmark Pharmaceuticals Ltd



- [Glenmark Generics settles litigation with Medicis Pharma](#)  
*Yahoo! India: Nov 16 2009 6:14AM Matching: glenmark pharmaceuticals*
- [Glenmark Pharmaceuticals wins USFDA approval for Ciclopirox cream](#)  
*Stockwatch.in: Nov 14 2009 10:32PM Matching: glenmark pharmaceuticals*
- [Glenmark Pharma gets USFDA nod for Ciclopirox cream](#)  
*MyIris: Nov 14 2009 4:22AM Matching: glenmark pharmaceuticals*
- [Warning Letters 2009](#)  
*U.S. Food and Drug Administration: Nov 14 2009 2:40AM Matching: glenmark pharmaceuticals*
- [Glenmark's consolidated revenue increases 5% in Q2](#)  
*Bio Spectrum Asia: Nov 2 2009 8:47AM Matching: glenmark pharmaceuticals*
- [Glenmark Pharmaceuticals may improve performance in Oct-Mar](#)  
*Livemint.com: Oct 29 2009 11:42PM Matching: glenmark pharmaceuticals*
- [Glenmark Pharma Q2 net dips 31 pc to Rs 80.88 crore](#)  
*EconomicTimes: Oct 29 2009 10:32AM Matching: glenmark pharmaceuticals*
- [Glenmark Pharma Q2 net down 31 percent](#)  
*Reuters India: Oct 29 2009 11:07AM Matching: glenmark pharmaceuticals*
- [Glenmark's consolidated net profit declines by 31% in Q2](#)  
*PharmaBiz: Oct 29 2009 9:39AM Matching: glenmark pharmaceuticals*
- [GLENMARK PHARMACEUTICALS LTD. - BONDS: GLENMARK GENERICS EUROPE ANNOUNCES THE LAUNCH OF ITS FIRST](#)  
*FinanzNachrichten.de: Oct 28 2009 12:28AM Matching: glenmark pharmaceuticals*
- [Additional CFTR inhibitor technology licensed to Napo Pharmaceuticals](#)  
*News-Medical.Net: Oct 26 2009 10:58AM Matching: glenmark pharmaceuticals*
- [Napo Acquires Rights to Additional CFTR Technology](#)  
*Pharmacy Choice: Oct 26 2009 9:48PM Matching: glenmark pharmaceuticals*
- [Napo Acquires Rights to Additional CFTR Technology](#)  
*Genetic Engineering News: Oct 26 2009 11:25AM Matching: glenmark pharmaceuticals*
- [Napo Acquires Rights to Additional CFTR Technology](#)  
*Yahoo! Canada: Oct 26 2009 1:23PM Matching: glenmark pharmaceuticals*

- [USFDA ISSUES WARNING TO INDIA'S GLENMARK FOR SELLING UNAPPROVED DRUG](#)  
*Individual.com: Oct 16 2009 9:35AM Matching: glenmark pharmaceuticals*

#### Glenmark Pharmaceuticals Ltd Clinical Trials:



- [A Clinical Study of Oglemilast in Patients With Mild to Moderate Persistent Asthma](#)

#### Glenmark Pharmaceuticals Ltd Patents:



- 7563900- [Process for the preparation N-\(3,5-dichloropyrid-4-yl\)-4-difluoromethoxy-8-methane\\_sulfonamido-dibenzo\[b,d\]furan-1-carboxamide](#)
- 7205323- [Dipeptidyl peptidase IV inhibitors pharmaceutical compositions containing them, and process for their preparation](#)
- 7223789- [Heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them](#)
- 7230002- [Dipeptidyl peptidase IV inhibitors; processes for their preparation and compositions thereof](#)
- 7238725- [Tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them](#)
- 7291745- [Process for the preparation of perindopril](#)
- 7312329- [Process for the preparation of pyrimidine derivatives](#)
- 7384962- [Heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them](#)
- 7393846- [Heterocyclic compounds useful for the treatment of inflammatory and allergic disorders](#)
- 7414143- [Process for the preparation of 4,4-dimethyl-6-ethynylthiochroman](#)
- 7524844- [Dipeptidyl peptidase IV inhibitors, process for their preparation and compositions containing them](#)
- 7538128- [Dipeptidyl peptidase IV inhibitors, process for their preparation and compositions containing them](#)
- 6963002- [Process for the preparation of 4,4-dimethyl-6-ethynylthiochroman](#)

## BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services.

BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

